Rapid Micro Biosystems Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Rapid Micro Biosystems wird ein jährliches Gewinn- und Umsatzwachstum von 10.4% bzw. 27.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -66.6% betragen.

Wichtige Informationen

10.4%

Wachstumsrate der Gewinne

17.7%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	16.2%
Wachstumsrate der Einnahmen	27.3%
Zukünftige Eigenkapitalrendite	-66.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	06 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Oct 10

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

May 09

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Mar 08

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Feb 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RPID - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	51	-38	N/A	N/A	1
12/31/2025	37	-44	N/A	N/A	3
12/31/2024	27	-47	N/A	N/A	3
3/31/2024	23	-52	-46	-44	N/A
12/31/2023	23	-52	-47	-45	N/A
9/30/2023	21	-58	-49	-47	N/A
6/30/2023	19	-61	-56	-53	N/A
3/31/2023	18	-60	-64	-58	N/A
12/31/2022	17	-61	-65	-59	N/A
9/30/2022	18	-59	-68	-60	N/A
6/30/2022	20	-68	-71	-64	N/A
3/31/2022	22	-69	-66	-61	N/A
12/31/2021	23	-78	-58	-55	N/A
9/30/2021	23	-77	-49	-47	N/A
6/30/2021	22	-63	-38	-37	N/A
3/31/2021	18	-60	-35	-34	N/A
12/31/2020	16	-45	-32	-31	N/A
12/31/2019	17	-27	-23	-21	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RPID wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RPID wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RPID wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RPIDDie Einnahmen des Unternehmens (27.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: RPIDDie Einnahmen des Unternehmens (27.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RPID wird voraussichtlich in 3 Jahren unrentabel sein.

Rapid Micro Biosystems Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Full Year of 2023

Consensus revenue estimates fall by 11%

Rapid Micro Biosystems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Price target decreased to US$9.00

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. to Report Q1, 2024 Results on May 03, 2024

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024

Rapid Micro Biosystems, Inc. to Report Fiscal Year 2023 Results on Mar 01, 2024

Rapid Micro Biosystems, Inc. Receives A Non-Compliance Notification Letter from the Nasdaq

Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023

Rapid Micro Biosystems, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Rapid Micro Biosystems Receives a Notification Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Rapid Micro Biosystems, Inc. Appoints of Kirk Malloy as Chair of Its Board of Directors

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Full Year of 2023

Consensus revenue estimates fall by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2022 Results on Mar 03, 2023

Rapid Micro Biosystems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Rapid Micro Biosystems, Inc. Announces Publication of Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$9.00

Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.71 loss in 3Q 2021)

Rapid Micro Biosystems, Inc. Reaffirms Full Year 2022 Revenue Outlook

Rapid Micro Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Rapid Micro Biosystems, Inc. Announces RMBnucleus Mold Alarm for the Growth Direct System

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Kennedy Lewis Capital Partners Master Fund II LP and Kennedy Lewis Capital Partners Master Fund III LP managed by Kennedy Lewis Investment Management LLC cancelled the acquisition of remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID).

Rapid Micro Biosystems, Inc. Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Rapid Micro Biosystems, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Kennedy Lewis Investment Management LLC delivered a Non-Binding Proposal to acquire remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID) for approximately $160 million.

Rapid Micro Biosystems, Inc.(NasdaqGS:RPID) dropped from Russell 2500 Value Index

Rapid Micro Biosystems, Inc. Reaffirms Earnings Guidance For Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2022

Alexander Schmitz Not to Stand for Reelection as Member of the Board of Directors of Rapid Micro Biosystems, Inc

Insider recently bought US$70k worth of stock

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance Full Year 2022

Full year 2021 earnings: Revenues in line with analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2021 Results on Mar 04, 2022

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Rapid Micro Biosystems Provides Revenue Guidance for the Full Year 2022

Third quarter 2021 earnings released: US$0.71 loss per share

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year of 2021

Rapid Micro Biosystems, Inc. has completed an IPO in the amount of $158.4 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken